Large-scale genotyping identifies 41 new loci associated with breast cancer risk. by Michailidou, K et al.
Large-scale genotyping identifies 41 new loci associated with
breast cancer risk
Kyriaki Michailidou1,138, Per Hall2,138, Anna Gonzalez-Neira3, Maya Ghoussaini4, Joe
Dennis1, Roger L Milne5, Marjanka K Schmidt6,7, Jenny Chang-Claude8, Stig E Bojesen9,10,
Manjeet K Bolla1, Qin Wang1, Ed Dicks4, Andrew Lee1, Clare Turnbull11, Nazneen
Rahman11, The Breast and Ovarian Cancer Susceptibility Collaboration12, Olivia
Fletcher13, Julian Peto14, Lorna Gibson14, Isabel dos Santos Silva14, Heli Nevanlinna15,
Taru A Muranen15, Kristiina Aittomäki16, Carl Blomqvist17, Kamila Czene2, Astrid
Irwanto18, Jianjun Liu18, Quinten Waisfisz19, Hanne Meijers-Heijboer19, Muriel Adank19,
Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)12, Rob B van
der Luijt20, Rebecca Hein8,21, Norbert Dahmen22, Lars Beckman23, Alfons Meindl24, Rita K
Correspondence should be addressed to: D.F.E. (dfe20@medschl.cam.ac.uk) or P.H. (per.hall@ki.se).
12A list of members is provided in the Supplementary Note
138These authors contributed equally to this work.
Note: Supplementary information is available in the online version of the paper.
COMPETING FINANCIAL INTERESTS
The authors declare no competing financial interests.
Reprints and permissions information is available online at http://www.nature.com/reprints/index.html.
AUTHOR CONTRIBUTIONS
K. Michailidou and D.F.E. performed the statistical analysis and drafted the manuscript. D.F.E. conceived and coordinated the
synthesis of the iCOGS array and led BCAC. P.H. coordinated COGS. J. Benitez led the iCOGS genotyping working group. A.G.-N.,
G.P., M.R.A., J. Benitez, D.V., F.B., D.C.T., J. Simard, A.M.D. and C.L. coordinated genotyping of the iCOGS array. M.G.-C.,
P.D.P.P. and M.K.S. led the BCAC pathology and survival working group. J.C.-C. led the BCAC risk factor working group. A.M.D.
and G.C.-T. led the iCOGS quality control working group. J.D., E.D., M. Ghoussaini and A. Lee provided bioinformatics support.
M.K.B. and Q. Wang provided data management support for BCAC. S.C. and L.F.A.W. provided analysis of the TCGA expression
data. C.T., N.R. and D.F.E. led the UK2 GWAS. O.F., J.P. and I.d.S.S. led the BBCS GWAS. H.N., T.A.M., K. Aittomäki and C.B.
led the HEBCS GWAS. P.H., K.C., A.I. and J. Liu led the SASBAC GWAS. Q. Waisfisz, H.M.-H., M.A. and R.B.v.d.L. led the
DFBBCS GWAS. J.C.-C., R.H., N.D. and L. Beckman led the MARIE GWAS. A. Meindl, R.K.S., B.M.-M. and P.L. led the GC-
HBOC GWAS. J.L.H., M.C.S., E.M., D.F.S. and H.T. led the ABCFS GWAS. A.G.U. and A. Hofman led the genotyping in the
Rotterdam study. D.J.H. and S.J.C. led the CGEMS GWAS. F.J.C. and S. Slager coordinated TNBCC. C.A.H., B.E.H., F.S. and
L.L.M. coordinated MEC. P.D.P.P., D.F.E. and M. Shah coordinated SEARCH. R.L. coordinated EPIC-Norfolk. J. Brown
coordinated SIBS. P.H., K.C., N.S., K.H. and J. Li coordinated SASBAC and pKARMA. S.E.B., B.G.N., S.F.N. and H.F. coordinated
CGPS. F.J.C., X.W., C.V. and K.N.S. coordinated MCBCS. D.L., M.M., R.P. and M.-R.C. coordinated LMBC. J.C.-C., A.R., S.N.
and D.F.-J. coordinated MARIE. N.J., L.G. and Z.A. coordinated BBCS. K. Aaltonen and T.H. coordinated HEBCS. M.K.S., A.B.,
L.J.V.t.V. and C.E.v.d.S. coordinated ABCS. P.G., T.T., P.L.-P. and F. Menegaux coordinated CECILE. F. Marme, A. Schneeweiss,
C. Sohn and B. Burwinkel coordinated BSUCH. R.L.M., A.G.-N., M.P.Z., J.I.A.P. and J. Benitez coordinated CNIO-BCS. A.C.,
I.W.B., S.S.C. and M.W.R.R. coordinated SBCS. E.J.S., I.T., M.J.K. and N.M. coordinated BIGGS. I.L.A., J.A.K., G.G. and A.M.M.
coordinated OFBCR. A. Lindblom and S. Margolin coordinated KARBAC. M.J.H., A. Hollestelle, A.M.W.v.d.O. and A. Jager
coordinated RBCS. J.L.H., M.C.S., Q.M.B., J. Stone, G.S.D. and C.A. coordinated ABCFS. J.L.H., M.C.S., G.G.G., G.S. and L.
Baglietto coordinated MCCS. P.A.F., L.H., A.B.E. and M.W.B. coordinated BBCC. H. Brenner, H. Müller, V.A. and C. Stegmaier
coordinated ESTHER. A. Swerdlow, A.A., N.O., M.J. and M.G.-C. coordinated UKBGS. M.G.-C., J.F., J. Lissowska and L. Brinton
coordinated PBCS. M.S.G., F.L., M.D. and J. Simard coordinated MTLGEBCS. R.W., K.P., A.J.-V. and M. Grip coordinated OBCS.
H. Brauch, U.H. and T.B. coordinated GENICA. P.R., P.P., S. Manoukian and B. Bonanni coordinated MBCSG. P.D., R.A.E.M.T., C.
Seynaeve and C.J.v.A. coordinated ORIGO. A. Jakubowska, J. Lubinski, K.J. and K.D. coordinated SZBCS. A. Mannermaa, V.K.,
V.-M.K. and J.M.H. coordinated KBCP. N.V.B., N.N.A. and T.D. coordinated HMBCS. V.N.K. coordinated NBCS. H.A.-C.
coordinated UCIBCS. A.E.T. coordinated OSU. S.E. coordinated RPCI. F.F. coordinated DEMOKRITOS. D.K., K.-Y.Y. and D.-Y.N.
coordinated SEBCS. K. Matsuo, H. Ito, H. Iwata and A. Sueta coordinated HERPACC. A.H.W., C.-C.T., D.V.D.B. and D.O.S.
coordinated LAABC. W.Z., X.-O.S., W.L., Y.-T.G. and H.C. coordinated SGBCS. S.H.T., C.H.Y., S.Y.P. and B.K.C. coordinated
MYBRCA. M.H., H. Miao, W.Y.L. and J.-H.S. coordinated SGBCC. K. Muir, A. Lophatananon, S.S.-B. and P.S. coordinated ACP.
C.-Y.S., C.-N.H., P.-E.W. and S.-L.D. coordinated TWBCS. S. Sangrajrang, V.G., P.B. and J.M. coordinated TBCS. W.J.B., L.B.S.,
Q.C. and W.Z. coordinated SCCS. W.Z., S.D.-H., M. Shrubsole and J. Long coordinated NBHS. G.C.-T. coordinated the genotyping
component of kConFab. All authors provided critical review of the manuscript.
NIH Public Access
Author Manuscript
Nat Genet. Author manuscript; available in PMC 2014 April 01.
Published in final edited form as:
Nat Genet. 2013 April ; 45(4): 353–361e2. doi:10.1038/ng.2563.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Schmutzler25,26, Bertram Müller-Myhsok27, Peter Lichtner28, John L Hopper29, Melissa C
Southey30, Enes Makalic29, Daniel F Schmidt29, Andre G Uitterlinden31, Albert Hofman32,
David J Hunter33, Stephen J Chanock34, Daniel Vincent35, François Bacot35, Daniel C
Tessier35, Sander Canisius36, Lodewyk F A Wessels36, Christopher A Haiman37, Mitul
Shah4, Robert Luben1, Judith Brown1, Craig Luccarini4, Nils Schoof2, Keith Humphreys2,
Jingmei Li18, Børge G Nordestgaard9,10, Sune F Nielsen9,10, Henrik Flyger38, Fergus J
Couch39, Xianshu Wang39, Celine Vachon40, Kristen N Stevens40, Diether Lambrechts41,42,
Matthieu Moisse41,42, Robert Paridaens43, Marie-Rose Christiaens43, Anja Rudolph8, Stefan
Nickels8, Dieter Flesch-Janys8,44,45, Nichola Johnson13, Zoe Aitken14, Kirsimari
Aaltonen15,16,17, Tuomas Heikkinen15, Annegien Broeks6, Laura J Van’t Veer6, C Ellen van
der Schoot46, Pascal Guénel47,48, Thérèse Truong47,48, Pierre Laurent-Puig49, Florence
Menegaux47,48, Frederik Marme50,51, Andreas Schneeweiss50,51, Christof Sohn50, Barbara
Burwinkel50,52, M Pilar Zamora53, Jose Ignacio Arias Perez54, Guillermo Pita3, M Rosario
Alonso3, Angela Cox55, Ian W Brock55, Simon S Cross56, Malcolm W R Reed55, Elinor J
Sawyer57, Ian Tomlinson58,59, Michael J Kerin60, Nicola Miller60, Brian E Henderson37,
Fredrick Schumacher37, Loic Le Marchand61, Irene L Andrulis62,63, Julia A Knight64,65,
Gord Glendon62, Anna Marie Mulligan66,67, kConFab Investigators12, Australian Ovarian
Cancer Study Group12, Annika Lindblom68, Sara Margolin69, Maartje J Hooning70,
Antoinette Hollestelle70, Ans M W van den Ouweland71, Agnes Jager70, Quang M Bui29,
Jennifer Stone29, Gillian S Dite29, Carmel Apicella29, Helen Tsimiklis30, Graham G
Giles29,72, Gianluca Severi29,72, Laura Baglietto29,72, Peter A Fasching73,74, Lothar
Haeberle73, Arif B Ekici75, Matthias W Beckmann73, Hermann Brenner76, Heiko Müller76,
Volker Arndt76, Christa Stegmaier77, Anthony Swerdlow11, Alan Ashworth13,78, Nick
Orr13,78, Michael Jones11, Jonine Figueroa34, Jolanta Lissowska79, Louise Brinton34, Mark
S Goldberg80,81, France Labrèche82, Martine Dumont83, Robert Winqvist84, Katri Pylkäs84,
Arja Jukkola-Vuorinen85, Mervi Grip86, Hiltrud Brauch87,88, Ute Hamann89, Thomas
Brüning90, The GENICA (Gene Environment Interaction and Breast Cancer in Germany)
Network12, Paolo Radice91,92, Paolo Peterlongo91,92, Siranoush Manoukian93, Bernardo
Bonanni94, Peter Devilee95,96, Rob A E M Tollenaar97, Caroline Seynaeve98, Christi J van
Asperen99, Anna Jakubowska100, Jan Lubinski100, Katarzyna Jaworska100,101, Katarzyna
Durda100, Arto Mannermaa102,103,104, Vesa Kataja104,105,106, Veli-Matti Kosma102,103,104,
Jaana M Hartikainen102,103,104, Natalia V Bogdanova107,108, Natalia N Antonenkova109,
Thilo Dörk107, Vessela N Kristensen110,111, Hoda Anton-Culver112, Susan Slager40, Amanda
E Toland113, Stephen Edge114, Florentia Fostira115, Daehee Kang116, Keun-Young Yoo116,
Dong-Young Noh116, Keitaro Matsuo117, Hidemi Ito117, Hiroji Iwata118, Aiko Sueta117, Anna
H Wu37, Chiu-Chen Tseng37, David Van Den Berg37, Daniel O Stram37, Xiao-Ou Shu119, Wei
Lu120, Yu-Tang Gao121, Hui Cai119, Soo Hwang Teo122,123, Cheng Har Yip123, Sze Yee
Phuah122, Belinda K Cornes124, Mikael Hartman125,126, Hui Miao125, Wei Yen Lim125, Jen-
Hwei Sng126, Kenneth Muir127, Artitaya Lophatananon127, Sarah Stewart-Brown127,
Pornthep Siriwanarangsan128, Chen-Yang Shen129,130, Chia-Ni Hsiung129, Pei-Ei Wu131,
Shian-Ling Ding132, Suleeporn Sangrajrang133, Valerie Gaborieau134, Paul Brennan134,
James McKay134, William J Blot119,135, Lisa B Signorello119,135, Qiuyin Cai119, Wei
Zheng119, Sandra Deming-Halverson119, Martha Shrubsole119, Jirong Long119, Jacques
Simard83, Montse Garcia-Closas11,13,78, Paul D P Pharoah1,4, Georgia Chenevix-Trench136,
Alison M Dunning4, Javier Benitez3,137, and Douglas F Easton1,4
1Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care,
University of Cambridge, Cambridge, UK 2Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm, Sweden 3Human Genotyping Unit–Centro Nacional de Genotipado
(CEGEN), Human Cancer Genetics Programme, Spanish National Cancer Research Centre
(CNIO), Madrid, Spain 4Centre for Cancer Genetic Epidemiology, Department of Oncology,
University of Cambridge, Cambridge, UK 5Genetic & Molecular Epidemiology Group, Human
Michailidou et al. Page 2
Nat Genet. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Cancer Genetics Programme, CNIO, Madrid, Spain 6Division of Molecular Pathology,
Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
7Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van
Leeuwenhoek Hospital, Amsterdam, The Netherlands 8Division of Cancer Epidemiology,
Deutsches Krebsforschungszentrum, Heidelberg, Germany 9Copenhagen General Population
Study, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark 10Department of
Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark
11Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, UK
13Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
14Department of Non-communicable Disease Epidemiology, London School of Hygiene and
Tropical Medicine, London, UK 15Department of Obstetrics and Gynecology, University of Helsinki
and Helsinki University Central Hospital, Helsinki, Finland 16Department of Clinical Genetics,
University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland 17Department of
Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
18Human Genetics Division, Genome Institute of Singapore, Singapore 19Section of
Oncogenetics, Department of Clinical Genetics, VU University Medical Center, Amsterdam, The
Netherlands 20Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The
Netherlands 21PMV (Primär Medizinische Versorgung) Research Group at the Department of
Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany
22Department of Psychiatry, University of Mainz, Mainz, Germany 23Institute for Quality and
Efficiency in Health Care (IQWiG), Cologne, Germany 24Division for Gynaecological Tumor
Genetics, Clinic of Gynaecology and Obstetrics, Technische Universität München, Munich,
Germany 25Centre of Familial Breast and Ovarian Cancer, University of Cologne, Cologne,
Germany 26Centre for Molecular Medicine (CMMC), University of Cologne, Cologne, Germany
27Max Planck Institute of Psychiatry, Munich, Germany 28Institute of Human Genetics, Helmholtz
Zentrum München–German Research Center for Environmental Health, Neuherberg, Germany
29Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of
Population Health, The University of Melbourne, Melbourne, Victoria, Australia 30Genetic
Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Melbourne,
Victoria, Australia 31Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The
Netherlands 32Department of Epidemiology, Erasmus Medical Center, Rotterdam, The
Netherlands 33Program in Molecular and Genetic Epidemiology, Harvard School of Public Health,
Boston, Massachusetts, USA 34Division of Cancer Epidemiology and Genetics, National Cancer
Institute, Rockville, Maryland, USA 35McGill University and Génome Québec Innovation Centre,
Montreal, Quebec, Canada 36Division of Molecular Carcinogenesis, Netherlands Cancer Institute,
Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands 37Department of Preventive
Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California,
USA 38Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital,
Copenhagen, Denmark 39Department of Laboratory Medicine and Pathology, Mayo Clinic,
Rochester, Minnesota, USA 40Department of Health Sciences Research, Mayo Clinic, Rochester,
Minnesota, USA 41Vesalius Research Center (VRC), VIB, Leuven, Belgium 42Laboratory for
Translational Genetics, Department of Oncology, University of Leuven, Leuven, Belgium
43Department of Oncology, University Hospital Gasthuisberg, University of Leuven, Leuven,
Belgium 44Department of Cancer Epidemiology/Clinical Cancer Registry, University Clinic
Hamburg-Eppendorf, Hamburg, Germany 45Institute for Medical Biometrics and Epidemiology,
University Clinic Hamburg-Eppendorf, Hamburg, Germany 46Sanquin Research, Amsterdam, The
Netherlands 47INSERM (National Institute of Health and Medical Research), CESP (Center for
Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of
Cancer, Villejuif, France 48Unité Mixte de Recherche Scientifique (UMRS) 1018, University Paris–
Sud, Villejuif, France 49UMRS 775, INSERM, Université Paris Sorbonne Cité, Paris, France
50Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany
Michailidou et al. Page 3
Nat Genet. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
51National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany
52Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg,
Germany 53Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain 54Servicio
de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain 55Cancer Research
UK/Yorkshire Cancer Research Sheffield Cancer Research Centre, Department of Oncology,
University of Sheffield, Sheffield, UK 56Academic Unit of Pathology, Department of Neuroscience,
University of Sheffield, Sheffield, UK 57Division of Cancer Studies, National Institute for Health
Research (NIHR) Comprehensive Biomedical Research Centre, Guy’s & St. Thomas’ National
Health Service (NHS) Foundation Trust in partnership with King’s College London, London, UK
58Welcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK 59Oxford
Biomedical Research Centre, University of Oxford, Oxford, UK 60Clinical Science Institute,
University Hospital Galway, Galway, Ireland 61University of Hawaii Cancer Center, Honolulu,
Hawaii, USA 62Ontario Cancer Genetics Network, Samuel Lunenfeld Research Institute, Mount
Sinai Hospital, Toronto, Ontario, Canada 63Department of Molecular Genetics, University of
Toronto, Toronto, Ontario, Canada 64Prosserman Centre for Health Research, Samuel Lunenfeld
Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada 65Division of Epidemiology,
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
66Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario,
Canada 67Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada
68Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
69Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden 70Department of
Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
71Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The
Netherlands 72Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria,
Australia 73University Breast Center Franconia, Department of Gynecology and Obstetrics,
University Hospital Erlangen, Friedrich-Alexander University Erlangen–Nuremberg, Erlangen,
Germany 74Division of Hematology and Oncology, Department of Medicine, David Geffen School
of Medicine, University of California, Los Angeles, Los Angeles, California, USA 75Institute of
Human Genetics, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
76Division of Clinical Epidemiology and Aging Research, DKFZ, Heidelberg, Germany 77Saarland
Cancer Registry, Saarbrücken, Germany 78Division of Breast Cancer Research, The Institute of
Cancer Research, London, UK 79Department of Cancer Epidemiology and Prevention, M.
Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
80Department of Medicine, McGill University, Montreal, Quebec, Canada 81Division of Clinical
Epidemiology, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec,
Canada 82Département de Médecine Sociale et Préventive, Département de Santé
Environnementale et Santé au Travail, Université de Montréal, Montreal, Quebec, Canada
83Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University,
Quebec City, Quebec, Canada 84Laboratory of Cancer Genetics and Tumor Biology, Department
of Clinical Genetics and Biocenter Oulu, University of Oulu, Oulu University Hospital, Oulu,
Finland 85Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland
86Department of Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland 87Dr.
Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany 88University of
Tübingen, Tübingen, Germany 89Molecular Genetics of Breast Cancer, DKFZ, Heidelberg,
Germany 90Institute for Prevention and Occupational Medicine of the German Social Accident
Insurance, Institute of the Ruhr–Universität Bochum (IPA), Bochum, Germany 91Unit of Molecular
Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine,
Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy 92Istituto FIRC di Oncologia
Molecolare (IFOM), Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy 93Unit of
Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS INT,
Milan, Italy 94Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan,
Michailidou et al. Page 4
Nat Genet. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Italy 95Department of Human Genetics, Leiden University Medical Center, Leiden, The
Netherlands 96Department of Pathology, Leiden University Medical Center, Leiden, The
Netherlands 97Department of Surgical Oncology, Leiden University Medical Center, Leiden, The
Netherlands 98Family Cancer Clinic, Department of Medical Oncology, Erasmus Medical Center–
Daniel den Hoed Cancer Center, Rotterdam, The Netherlands 99Department of Clinical Genetics,
Leiden University Medical Center, Leiden, The Netherlands 100Department of Genetics and
Pathology, Pomeranian Medical University, Szczecin, Poland 101Postgraduate School of
Molecular Medicine, Warsaw Medical University, Warsaw, Poland 102School of Medicine, Institute
of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio,
Finland 103Biocenter Kuopio, Cancer Center of Eastern Finland, University of Eastern Finland,
Kuopio, Finland 104Imaging Center, Department of Clinical Pathology, Kuopio University Hospital,
Kuopio, Finland 105School of Medicine, Institute of Clinical Medicine and Oncology, University of
Eastern Finland, Kuopio, Finland 106Cancer Center, Kuopio University Hospital, Kuopio, Finland
107Department of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany
108Department of Radiation Oncology, Hannover Medical School, Hannover, Germany 109NN
Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus 110Institute for
Clinical Epidemiology and Molecular Biology (EpiGen), Faculty of Medicine, University of Oslo,
Oslo, Norway 111Group of Cancer Genome Variation, Department of Genetics, Institute for
Cancer Research, Rikshospitalet-Radiumhospitalet, Oslo, Norway 112Department of
Epidemiology, University of California–Irvine, Irvine, California, USA 113Department of Molecular
Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State
University, Columbus, Ohio, USA 114Roswell Park Cancer Institute, Buffalo, New York, USA
115Molecular Diagnostics Laboratory, Institute of Radioisotopes and Radiodiagnostic Products
(IRRP), National Centre for Scientific Research Demokritos, Aghia Paraskevi Attikis, Athens,
Greece 116Seoul National University College of Medicine, Seoul, Korea 117Division of
Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
118Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan 119Division of
Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram
Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
120Shanghai Center for Disease Control and Prevention, Shanghai, China 121Department of
Epidemiology, Shanghai Cancer Institute, Shanghai, China 122Cancer Research Initiatives
Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia 123Breast Cancer Research
Unit, University Malaya Cancer Research Institute, University Malaya Medical Centre, Kuala
Lumpur, Malaysia 124Singapore Eye Research Institute, National University of Singapore,
Singapore 125Saw Swee Hock School of Public Health, National University of Singapore,
Singapore 126Department of Surgery, Yong Loo Lin School of Medicine, National University of
Singapore, Singapore 127Warwick Medical School, University of Warwick, Coventry, UK
128Ministry of Public Health, Bangkok, Thailand 129Institute of Biomedical Sciences, Academia
Sinica, Taipei, Taiwan 130Colleague of Public Health, China Medical University, Taichong, Taiwan
131Taiwan Biobank, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
132Department of Nursing, Kang-Ning Junior College of Medical Care and Management, Taipei,
Taiwan 133National Cancer Institute, Bangkok, Thailand 134International Agency for Research on
Cancer, Lyon, France 135International Epidemiology Institute, Rockville, Maryland, USA
136Department of Genetics, Queensland Institute of Medical Research, Brisbane, Queensland,
Australia 137Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain
Abstract
Breast cancer is the most common cancer among women. Common variants at 27 loci have been
identified as associated with susceptibility to breast cancer, and these account for ~9% of the
familial risk of the disease. We report here a meta-analysis of 9 genome-wide association studies,
including 10,052 breast cancer cases and 12,575 controls of European ancestry, from which we
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selected 29,807 SNPs for further genotyping. These SNPs were genotyped in 45,290 cases and
41,880 controls of European ancestry from 41 studies in the Breast Cancer Association
Consortium (BCAC). The SNPs were genotyped as part of a collaborative genotyping experiment
involving four consortia (Collaborative Oncological Gene-environment Study, COGS) and used a
custom Illumina iSelect genotyping array, iCOGS, comprising more than 200,000 SNPs. We
identified SNPs at 41 new breast cancer susceptibility loci at genome-wide significance (P < 5 ×
10−8). Further analyses suggest that more than 1,000 additional loci are involved in breast cancer
susceptibility.
Breast cancer is the most commonly occurring malignancy among women, with an
estimated 1 million new cases and over 400,000 deaths annually worldwide1. Familial
aggregation and twin studies have shown the substantial contribution of inherited
susceptibility to breast cancer2,3. Many genetic loci are known to contribute to this familial
risk, including genes with high-penetrance mutations (notably BRCA1 and BRCA2),
moderate-risk alleles in genes such as ATM, CHEK2 and PALB2, and common lower
penetrance alleles, of which 27 have been identified so far, principally through genome-wide
association studies (GWAS)4–16. In total, these loci explain approximately 30% of the
familial risk of breast cancer15. Global analysis of GWAS data suggests that a substantial
fraction of the residual aggregation can be explained by other common variants not yet
identified, but the relative contributions of common and rare variants are still uncertain.
RESULTS
To identify additional susceptibility loci for breast cancer, we first conducted a meta-
analysis of 9 breast cancer GWAS in populations of European ancestry, including 10,052
cases and 12,575 controls (Supplementary Table 1). From this analysis, we selected 35,084
SNPs on the basis of evidence of association with breast cancer, derived from a 1-degree-of-
freedom trend test, a test weighted for family history, a 2-degrees-of-freedom test and subset
analyses based on cases of breast cancer diagnosed before 40 years of age and before 50
years of age (Online Methods). In particular, we were able to select all SNPs or surrogate
SNPs with 1-degree-of-freedom Ptrend < 0.008. To evaluate these SNPs, we then designed a
custom Illumina iSelect genotyping array (iCOGS) in collaboration with three other
consortia studying, in addition to breast cancer risk, susceptibility to ovarian cancer, prostate
cancer and breast and ovarian cancers in BRCA1 and BRCA2 mutation carriers
(COGS)17–20. The array included, in addition to SNPs selected from GWAS, SNPs selected
for fine mapping of known susceptibility loci, functional candidate SNPs and SNPs related
to other traits (Online Methods and Supplementary Note). The iCOGS array comprised
211,155 SNPs. These arrays were used to genotype 114,255 DNA samples from 52 studies
participating in BCAC (Supplementary Table 2). After quality control exclusions (Online
Methods and Supplementary Table 3), data were obtained for 199,961 SNPs in 52,675 cases
and 49,436 controls. The analyses presented here are based on data from subjects of
European ancestry (45,290 cases and 41,880 controls from 41 studies) and focus on 29,807
SNPs that were selected on the basis of the GWAS analysis that were successfully
genotyped and were not located in regions previously known to be associated with breast
cancer.
The association between each SNP and breast cancer risk was tested using a 1-degree-of-
freedom trend test adjusted for study and seven principal components (Online Methods).
There was some evidence for inflation in the test statistics, detected using data from 22,897
uncorrelated SNPs on iCOGS not selected on the basis of breast cancer risk (λ = 1.20, λ1000
= 1.005; Supplementary Fig. 1a). There was, however, clear evidence of an excess of
statistically significant associations among the SNPs selected from the GWAS analysis
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(Table 1 and Supplementary Fig. 1b). Although some excess was also observed among the
SNPs not selected from the breast cancer GWAS, the excess of statistically significant
associations was much more marked among the GWAS SNPs at all levels of statistical
significance. In addition, of 21,128 SNPs not selected for breast cancer association that were
also present in the combined GWAS data set, 10,864 (51%) had effects in the same direction
in the GWAS and iCOGS data, and, for these SNPs, inflation was 1.26 (λ1000 = 1.007)
compared with 1.14 (λ1000 = 1.0035) for SNPs with effects in opposite directions in the two
stages. A similar direction of effect was seen for these SNPs in the combined GWAS (λ =
0.87 for SNPs with effects in the same direction versus λ = 0.79 for SNPs with effects in the
opposite direction, with inflation being <1 because SNPs showing evidence of association
were excluded). Taken together, these results suggest that much of the inflation in the test
statistics for SNPs not selected for breast cancer association is also due to the effect of true
associations. Moreover, some of the excess of statistically significant associations seen in
the SNPs not selected for breast cancer association was due to SNPs close to breast cancer–
associated SNPs. For example, of the 45 SNPs with significant association at P < 0.00001,
21 were within 1 Mb of 1 of the newly identified breast cancer loci identified at our set
genome-wide significance threshold. Taken together, these results strongly suggest that most
of the excess of significant association for the GWAS-selected SNPs reflect true
associations.
Of the 27 previously established breast cancer–associated loci, all but 4 showed clear
evidence of association with overall breast cancer risk in the iCOGS stage (P = 2.2 × 10−5 –
P = 5.9 × 10−125; Supplementary Table 4). Three loci showed weaker evidence for
association: rs1045485, encoding an Asp302His variant in CASP8, whose association was
previously identified in a candidate gene study (P = 0.054 in the iCOGS stage; P = 0.0013 in
combined data from the GWAS and iCOGS stages)21; rs2380205 at 10p15, identified in a
GWAS but suggested to be a possible false positive association in a previous BCAC
analysis22,23 (iCOGS P = 0.075; combined P = 0.0021); and rs8170 at 19p13.1, for which
the association has been shown to be specific to estrogen receptor (ER)-negative breast
cancer24 (P = 0.0027 in iCOGS; combined P = 0.0012). One locus, rs2284378 at 20q11,
recently shown to be associated with ER-negative breast cancer, was not selected for the
iCOGS array16.
Identification of new susceptibility loci
When the results from the GWAS and the iCOGS array were combined, 263 SNPs in 37
new regions had associations that reached P < 5 × 10−8 (Fig. 1, Table 2 and Supplementary
Figs. 2 and 3). In four regions (5q11.2, 8q21.11, 10p12.31 and 18q11.2), this set of SNPs
included SNPs within 1 Mb of each other that were uncorrelated, such that a second SNP
was associated with disease after adjustment for the most significantly associated SNP
(Supplementary Fig. 4 and Supplementary Table 5). There was little or no evidence for
heterogeneity in the per-allele odds ratios (ORs) among studies for any SNP (per-SNP I2 and
P values are given in Supplementary Fig. 2 and Supplementary Table 6). Genotype-specific
OR estimates were consistent with a log-additive (allele dose) model for most SNPs, with
the exception of three SNPs (rs616488, rs204247 and rs720475) for which the heterozygotes
had a similar OR as homozygotes for the high-risk allele and two SNPs (rs11242675 and
rs6472903) that were more consistent with a recessive model (Supplementary Table 6).
Consistent with the pattern seen for previously established loci, there was strong evidence
for specificity of the association to tumor subtype. For 13 of the loci, the per-allele OR was
higher for ER-positive disease than for ER-negative disease (case-only P < 0.05), in most
instances with little or no evidence of an association with ER-negative disease (based on
data from 7,465 ER-negative cases and 27,074 ER-positive cases; Supplementary Table 7a).
The most notable differences were for SNP rs6828523 at 4q34.1 (ER-positive OR = 0.87
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(95% confidence interval (CI) = 0.84–0.90); ER-negative OR = 1.01 (95% CI = 0.96–1.07);
P for difference = 1.2 × 10−7) and for rs7072776 at 10p12.31, where the estimated effects
were in opposite directions (ER-positive OR = 1.09 (95% CI = 1.06–1.12); ER-negative OR
= 0.94 (95% CI = 0.90–0.98); P for difference = 3.1 × 10−10). No such difference was
observed for the neighboring SNP rs11814448, which was associated with both ER-positive
and ER-negative disease in the same direction. For one locus, SNP rs17817449 on
chromosome 16, the association was stronger for ER-negative than for ER-positive disease
(P for difference = 0.039). All SNPs showed comparable ORs for invasive and in situ
disease (based on data from 2,335 ductal carcinoma in situ, DCIS, and 42,118 invasive
cases), with the exceptions of rs12493607 and rs3903072, for which associations seemed to
be restricted to invasive disease (Supplementary Table 7b). Two loci (rs2588809 at 14q24.1
(P = 0.001) and rs941764 at 14q32.12 (P = 0.007)) showed higher per-allele ORs for cases
diagnosed at a young age (Supplementary Table 7c). Consistent with the predictions of a
polygenic model of susceptibility25, for 26 of the loci, the estimated OR was higher when
restricted to cases with a positive family history for disease (significant at P < 0.05 for 5
loci), whereas for only 6 loci was the OR lower when restricted to cases with a positive
family history (Supplementary Table 7d).
Four of the newly associated loci (rs16857609 at 2q35, rs10759243 at 9q31, rs11199914 at
10q26 and rs2588809 at 14q24) lie close to regions previously associated with breast cancer
risk. In each locus, however, the lead SNP was not correlated with the most strongly
associated known association, and the association of the new SNP remained similarly
statistically significant after adjustment for the previously associated SNP (Supplementary
Table 5). In the case of rs2588809, which lies in RAD51B (also known as RAD51L1), the
association was markedly stronger for ER-positive disease (P = 0.011; Supplementary Table
7a), whereas the previously associated SNPs (rs999737 and rs10483813), which lie ~370 kb
telomeric, are associated with similar ORs for both ER-positive and ER-negative disease26.
Two associated loci lie within or close to known breast cancer susceptibility genes.
rs11571833 is a polymorphic variant in BRCA2 that introduces a premature stop codon
(p.Lys3326*), previously reported to have no association with breast cancer risk27. The
results from the current study, however, indicate that this variant is associated with a
modestly higher risk of breast cancer. Further work will be required to determine whether
this association is due to a higher risk variant or variants in linkage disequilibrium (LD).
SNP rs132390 at 22q12 lies within an intron of EMID1 but is ~500 kb upstream of CHEK2,
raising the possibility that this association is mediated through the latter. CHEK2 c.
1100delC, the major deleterious CHEK2 variant in European populations28, occurs more
frequently in association with the risk allele at rs132390 (r2 = 0.06); however, the
association between r132390 and breast cancer risk persisted after adjustment for CHEK2 c.
1100delC, although attenuated (unadjusted OR in iCOGS = 1.12, P = 5.9 × 10−6; adjusted
OR = 1.09, P = 0.04).
In addition to rs11571833, one further SNP is a coding variant: rs11552449 encodes a
missense substitution p.His61Tyr in DCLRE1B (also known as SNM1B), an evolutionarily
conserved gene involved in DNA stability and the repair of interstrand cross-links29. The
remaining loci are either intronic (20) or intergenic (19). Two loci lie within genes
previously proposed as candidate breast cancer susceptibility genes. SNP rs12493607 lies in
intron 2 of TGFBR2. An analysis of genes in the transforming growth factor (TGF)-β
signaling pathway in European populations found weak evidence of an association between
rs4522809 and breast cancer risk (P = 0.02)30. This SNP is weakly correlated with
rs12493607 (r2 = 0.25) and also showed some evidence of association in our study, although
weaker than that seen for rs12493607 (iCOGS P = 0.00096; combined analysis of GWAS
and iCOGS P = 0.0029). A similar analysis of candidate SNPs in Asian populations
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identified SNP rs1078985 as a potential breast cancer susceptibility variant31. This variant,
however, was uncorrelated with rs12493607 in Europeans and showed no evidence of
association in our study (P = 0.33 in the iCOGS stage). SNP rs7904519 lies in intron 4 of
TCF7L2. A previous candidate gene study found weak evidence for an association between
a correlated SNP, rs12255372, associated with type 2 diabetes (r2 = 0.37 with rs7904519),
and familial breast cancer (P = 0.04)32.
The identification of the genes and variants underlying these associations will require more
detailed fine mapping and functional analysis. Nevertheless, it is possible to discern some
patterns. We identified 53 genes within 50 kb of the lead SNPs in the newly associated
regions, totaling 96 genes when including the previously known loci. Analysis using
Ingenuity Systems Pathway Analysis (IPA) identified an excess of genes reported to be
involved in tumorigenesis (34 genes; P = 0.0005), breast cancer (15 genes; P = 2 × 10−5) and
tumor incidence in model systems (10 genes; P = 2 × 10−7). The most consistently over-
represented functions were cell death (P = 0.0028), differentiation (P = 2 × 10−5) and
expression (P = 2 × 10−8).
Three loci are located in the vicinity of susceptibility regions for other cancer types. SNP
rs11780156 lies ~400 kb downstream of MYC. Previous GWAS have identified multiple
loci upstream of MYC that are associated with different cancer types, including a locus for
breast cancer. Functional studies have indicated that these associations might be mediated
through transcriptional regulation of MYC. The newly associated locus is ~300 kb
centromeric to a previously reported susceptibility locus for ovarian cancer, rs10088218, but
is uncorrelated with it (r2 = 0.02, based on data from European subjects in BCAC), raising
the possibility that these loci might also be regulating MYC33. SNP rs9790517 at 4q24 lies
~20 kb away from SNP rs7679673, previously reported to be associated with prostate
cancer34, and is correlated with it (r2 = 0.53). SNP rs9790517 lies in intron 11 of TET2,
which encodes a methylcytosine dioxygenase involved in myelopoiesis. Mutations in TET2
are frequent in hematological malignancies but have also been reported in 2 of 47 breast
tumors in the Catalogue of Somatic Mutations in Cancer (COSMIC) database. In addition,
Pharoah et al.18 have found an association between rs1243180 and ovarian cancer. This SNP
is ~120 kb telomeric to rs7072776 and is partially correlated with it (r2 = 0.51); both SNPs
and the neighboring breast cancer–associated locus rs11814448 lie within the region 400 kb
upstream of DNAJC1.
To further investigate the likely genes underlying the susceptibility variants, we examined
associations between the lead SNPs and the RNA expression of neighboring genes in 473
primary breast tumors and 61 normal breast tissue samples in The Cancer Genome Atlas
(TCGA) database. We found strong evidence for an association between rs616402 (a
surrogate for rs616488; r2 = 0.66) and expression of PEX14 in both tumor (P = 4.7 × 10−12)
and normal tissue (P = 0.00018; Supplementary Table 8), between rs3760983 (a surrogate
for rs3760982; r2 = 1) and expression of both ZNF404 (P = 1.2 × 10−6 in tumors) and
ZNF283 (P = 0.0089) and between rs3903072 and expression of CTSW (P = 4.9 × 10−5).
SNP rs3760982 was also found to be associated with the expression of ZNF45 (P = 0.0077),
ZNF283 (P = 0.05) and ZNF222 (P = 0.01) in lymphoblastoid cell lines from HapMap
samples using the Genevar database35 (Supplementary Table 8c). After adjustment for the
SNP in the region most strongly associated with expression, SNP rs616488 and PEX14 (P =
0.0071) as well as rs1217396 (a proxy for rs11552449) and PTPN22 (P = 0.0055) and
DCLRE1B (P = 0.0067) reached nominal significance at P < 0.01 (Supplementary Table
8a). Although none of these passed Bonferroni correction for multiple testing, the three
associations found exceeded the number expected by chance with 46 associations tested.
This supports some transcriptional effect from the risk-associated SNPs. PEX14 is involved
in peroxisome organization and protein and transmembrane transport; mutations in PEX14
Michailidou et al. Page 9
Nat Genet. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
have been associated with Zellweger syndrome36. The functions of ZNF45, ZNF222 and
ZNF283 are unknown but may involve transcriptional regulation.
In addition to the genes described above, plausible candidate genes exist in several of the
newly associated regions. MUS81 at 11q13 has a key role in the maintenance of genomic
stability and in DNA repair pathways37,38, and the cofilin gene (CFL1) is required for tumor
cell motility and invasion, particularly in mammary tumors39,40. Several other genes have
been associated with tumor aggressiveness; these include PTH1R at 3p21, FOXQ1 at 6p25,
ARHGEF5 at 7q35 and MKL1 at 22q13. PTH1R is the receptor for PTHLH, encoded by a
previously identified breast cancer susceptibility locus15. PTHLH is required for normal
mammary gland function and has been shown to be involved in the metastasis of breast
cancer cells to bone41,42. FOXQ1 encodes a transcription factor with a key role in cell
proliferation and migration and in breast cancer metastasis43. Alterations in its expression
level induce mesenchymal-epithelial transition44. Dysfunctional ARHGEF5 acts as an
oncogene specific for human breast tissue, with a crucial role in tumorigenesis and
metastasis in breast cancer45. MKL1 is also involved in tumor cell invasion and metastasis,
particularly in human breast carcinoma46. Two of the newly associated SNPs lie within the
TCF7L2 and FTO genes, previously associated with type 2 diabetes and/or obesity through
GWAS47–49. TCF7L2 acts as a proto-oncogene and is involved in the Wnt pathway and in
tumor formation50. PAX9 at 14q13.3 encodes a transcription factor that regulates cell
proliferation, migration and resistance to apoptosis51,52. SSBP4 is involved in DNA
recombination and repair and has been suggested to have tumor suppressor activity53,54. The
expression of KREMEN1 at 22q12.1 is lower or absent in human tumors compared to
normal tissue55,56. This gene encodes a negative regulator of the Wnt/β-catenin pathway,
which has a key role in cell fate determination, stem cell regulation and cell differentiation
and proliferation. It has been suggested that lack of KREMEN1 would activate the Wnt/β-
catenin pathway, thereby enhancing susceptibility to tumorigenesis55,56. Finally, NTN4 at
12q22 encodes a secreted growth factor that regulates tumor growth. High levels of NTN4
have been found in ER-positive but not ER-negative breast tumors57. NTN4 expression in
tumors has also been suggested as a potential prognostic marker for breast cancer57.
Overall contribution to breast cancer susceptibility
On the assumption that the risks conferred by common susceptibility loci combine
multiplicatively (no interaction on a log-additive scale) and on the basis of the per-allele OR
estimates from the iCOGS stage, we determined that the 41 newly associated loci explain
approximately 5% of the familial risk of breast cancer. However, the overall excess of
significant associations for SNPs selected from the breast cancer GWAS for genotyping in
the iCOGS stage suggests that a much larger number of loci contribute to susceptibility,
although they did not have associations reaching genome-wide levels of significance in the
current study. To assess this hypothesis more formally, we identified a set of 10,668 SNPs
selected from the GWAS that were uncorrelated (r2 < 0.1 between any pair). Of these, the
estimated OR was in the same direction as in the combined GWAS for 5,918 SNPs and in
the opposite direction for 4,750 SNPs. Assuming that SNPs with effects in opposite
directions are not associated with risk, an estimated 1,168 loci selected from the GWAS are
associated with risk. However, this is an underestimate because weakly associated SNPs
might have effects in opposite directions in the two stages. As an alternative approach, we
fitted the distribution of z scores for the iCOGS stage, aligned to the direction of the effect
in the GWAS, as a mixture of two normal distributions representing those SNPs that were or
were not associated with disease (Fig. 2 and Online Methods)58. On the basis of the
posterior probabilities from this analysis, an estimated 92% of loci (n = 9,815) were
associated with breast cancer risk (95% CI = 85–100%), and these contributed
approximately 18% of the familial risk of breast cancer. It should be noted, however, that
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the large majority of the loci had very small individual effects on risk: for example, the
estimated OR was >1.05 for only 10 loci, and 920 loci had an estimated OR of >1.02. When
taking into account effects from the previously known loci, these analyses suggest that
~28% of familial risk is explained by common variants selected for iCOGS, of which ~14%
can be explained by the 67 established loci (with a further ~20% due to higher penetrance
loci).
DISCUSSION
To our knowledge, this is the largest genetic association study in cancer so far. The power of
this approach is demonstrated by the fact that we have found evidence, at genome-wide
levels of significance, for more than 40 new susceptibility loci, more than doubling the
number of susceptibility loci for breast cancer. The effect sizes of the newly identified loci
are generally modest (the highest OR was 1.26). However, the very high levels of statistical
significance, the lack of heterogeneity among studies, the generally higher effect sizes for
familial cases and the fact that most of the excess of significant associations was
concentrated among SNPs selected on the basis of an association in the combined breast
cancer GWAS all indicate that these are robust associations. Although the majority of the
data are from populations of Northern and Western European ancestry, there was little or no
evidence of heterogeneity in the OR estimates between studies, indicating that the
associations apply broadly to populations of European ancestry. With more than 60
established breast cancer susceptibility loci, it is becoming possible to discern some more
general patterns among the loci. Although most of the underlying genes and variants remain
to be identified, there is a clear excess of genes either known to be involved in tumorigenesis
in model systems or involved in processes relevant to cancer, such as cell death and
differentiation. However, for other loci, such as PEX14, there is no obvious link to cancer
susceptibility. Nine of the new loci lie in chromosomal regions with no known genes,
suggesting that these may provide further examples of long-range regulation similar to that
seen in the 8q24 region59. We have identified three additional examples of loci in the
vicinity of susceptibility loci for other cancers (TET2, 8q24 and DNAJC1). These
associations might reflect the tissue-specific regulation of key genes, and understanding the
functional mechanisms underlying these associations may be particularly informative.
On the basis of the current set of loci and assuming that all loci combine multiplicatively,
the currently known loci now define a genetic profile for which 5% of the female population
has a risk that is ~2.3-fold higher than the population average and for which 1% of the
population has a risk that is ~3-fold higher. However, the large excess of significant
associations among the SNPs selected from the GWAS suggests that many more
susceptibility loci exist that have not met our threshold for genome-wide-significant
association in this study and that these explain a similar fraction of the heritability as the
currently known loci. The observation, made by comparing effect sizes in the iCOGS stage
with those in the GWAS, that a very large number of loci, perhaps several thousand,
contribute to polygenic susceptibility to breast cancer is consistent with results from GWAS
in other complex disorders such as schizophrenia, using a different analytical approach60.
Incorporating these loci into risk models should substantially improve disease prediction,
even if not all loci can be identified individually. Moreover, fine-scale mapping of the
identified regions may uncover more of the missing heritability, either through identifying a
more strongly associated variant (as found for the CCND1 locus; see French et al.61) or by
identifying additional signals (exemplified for the TERT region in Bojesen et al.62). Genetic
profiling using these common susceptibility loci in combination with rarer high-risk loci and
other risk factors may provide a rational basis for targeted breast cancer prevention.
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URLs
TCGA, http://cancergenome.nih.gov/; IPA, http://www.ingenuity.com/products/ipa;
COSMIC, http://www.sanger.ac.uk/genetics/CGP/cosmic/; BCAC, http://
ccge.medschl.cam.ac.uk/consortia/bcac/index.html; CIMBA, http://ccge.medschl.cam.ac.uk/
consortia/cimba/index.html; OCAC, http://ccge.medschl.cam.ac.uk/consortia/ocac/
index.html; PRACTICAL, http://ccge.medschl.cam.ac.uk/consortia/practical/index.html;
COGS, http://www.cogseu.org/; iCOGS, http://ccge.medschl.cam.ac.uk/research/consortia/
icogs/; Illumina GenCall, http://www.illumina.com/Documents/products/technotes/
technote_gencall_data_analysis_software.pdf; SNAP, http://www.broadinstitute.org/mpg/
snap/ldplot.php.
ONLINE METHODS
GWAS analysis
Primary genotype data were obtained for nine breast cancer GWAS in populations of
European ancestry (Supplementary Table 1). Standard quality control was performed on all
scans as follows. We excluded all individuals with low call rate (<95%) and extremely high
or low heterozygosity (P < 1 × 10−5), as well as all individuals evaluated to be of non-
European ancestry (>15% non-European component, as determined by multidimensional
scaling using the HapMap version 2 CEU, JPT/CHB and YRI populations as a reference).
We excluded SNPs with MAF < 1%; call rate < 95%; or call rate < 99% and MAF < 5% and
all SNPs with genotype frequencies that departed from Hardy-Weinberg equilibrium at P < 1
× 10−6 in controls or P < 1 × 10−12 in cases. For highly significant SNPs, genotype intensity
cluster plots were examined manually to judge reliability, either centrally or by contacting
the original investigators.
Data were imputed for all scans for ~2.6 million SNPs with the HapMap version 2 CEU
panel (Utah residents of Northern and Western European ancestry) as a reference, using the
program MaCH v1.0. Imputation was conducted separately for each scan. Estimated per-
allele ORs and standard errors were generated from the imputed genotypes using
ProbABEL63. For two studies (UK2 and HEBCS), estimates were adjusted by the first three
principal components, as this was found to materially reduce the inflation of test statistics.
Residual inflation was then adjusted for by multiplying the variance by a genomic control
adjustment factor, based on the ratio of the median χ2 test statistic to its expected value64.
BBCS and UK2 used the same control data (WTCCC2) but different genotyping platforms.
Data were imputed separately for these studies. For the combined analysis, the control set
was divided randomly between the two studies, in proportion to the size of the case series, to
provide disjoint strata. Overall significance tests for each SNP were performed using a
fixed-effects meta-analysis; data were only included for a given study if the imputation
accuracy r2 was >0.3.
SNP selection
Details of SNP selection for the iCOGS array are given in the Supplementary Note.
For the purpose of the BCAC analyses, we included SNPs on the basis of the analysis of the
nine GWAS described above. We ranked SNPs on the basis of the results from five
analyses: an overall 1-degree-of-freedom trend test; a 1-degree-of-freedom trend test giving
a weight of 2 to those studies selecting cases for a positive family history (UK2, BBCS,
DFBBCS and GC-HBOC); a 2-degrees-of-freedom genotype test; and 1-degree-of-freedom
tests based on cases diagnosed before the ages of 40 years or 50 years compared with all
controls. We also defined lists based on 1-degree-of-freedom trend tests restricted to data
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from each of the nine component studies. SNPs were also selected from analyses of cases
with ER-negative disease, but these are not reported here.
iCOGS genotyping
Samples for the iCOGS stage were drawn from 52 studies participating in BCAC, including
41 from populations of predominantly European ancestry, 9 of Asian ancestry and 2 of
African-American ancestry. The majority of studies were population-based or hospital-based
case-control studies, but some studies selected samples by age or oversampled for cases with
a family history of breast cancer (Supplementary Table 2). Studies were required to provide
~2% of samples in duplicate.
Genotyping was conducted using a custom Illumina Infinium array (iCOGS) in seven
centers, of which four were used for BCAC. Genotypes were called using Illumina’s
proprietary GenCall algorithm. Initial calling used a cluster file generated from 270 samples
from HapMap 2. To generate the final calls, we first selected a subset of 3,018 individuals,
including samples from each of the genotyping centers, each of the participating consortia
and each major ancestry group. Only plates with a consistently high call rate in the initial
calling were used. We also included 380 samples of European, Asian or African ancestry
genotyped as part of the HapMap Project and 1000 Genomes Project and 160 samples that
were known positive controls for rare variants on the array. This subset was used to generate
a cluster file that was then applied to call the genotypes for the remaining samples. We also
investigated two other calling algorithms: Illumnus65 and GenoSNP66. All three algorithms
were >99% concordant in their calling for 91% of the SNPs on the array. However, manual
inspection of a sample of the SNPs with discrepancies indicated that the calls from GenCall
were almost invariably superior (generally, because Illumnus or GenoSNP attempted to call
SNPs that clustered poorly). Therefore, only the genotypes called by GenCall have been
used in the analyses reported here.
Quality control
We excluded individuals for any of the following reasons: genotypically not female XX
(XY, XXY or XO); overall call rate < 95%; low or high heterozygosity (P < 1 × 10−6,
determined separately for individuals of European, East Asian and African-American
ancestry); genotypes discordant with those determined in previous BCAC genotyping such
that the individual appeared to be different; genotypes for the duplicate sample that seemed
to be from a different individual; and cryptic duplicates where the phenotypic data indicated
that the individuals were different. We searched for cryptic duplicates, both within each
study and between studies from the same country. For known and cryptic concordant
duplicates, the sample with the lower call rate was excluded. We attempted to identify first-
degree relative pairs using identity-by-state estimates based on ~37,000 uncorrelated SNPs.
For apparent first-degree relative pairs, we removed the control from a case-control pair;
otherwise, we excluded the individual with the lower call rate. For the main analyses
presented here, we also excluded 1,880 individuals who were included in any of the GWAS
to allow the GWAS and iCOGS stages to be combined.
Ancestry outliers were identified by multidimensional scaling, combining the iCOGS data
with genotypes from the HapMap 2 populations, on the basis of a subset of 37,000
uncorrelated markers that passed quality control (including ~1,000 that were selected as
ancestry-informative markers). Most studies were predominantly of a single ancestry
(European or East Asian), and individuals with >15% minority ancestry, as determined on
the basis of the first two principal components, were excluded. Two studies from Singapore
(SGBCC) and Malaysia (MYBRCA) contained a substantial fraction of individuals of mixed
European and Asian ancestry (likely of South Asian ancestry). For these studies, no
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exclusions for ancestry outliers were made, but principal-components analysis adequately
corrected for inflation in these studies. Similarly, for the two African-American studies
(NBHS and SCCS), no exclusions for ancestry outliers were made.
Principal-components analyses were carried out separately for the European, Asian and
African-American subgroups, on the basis of a subset of 37,000 uncorrelated SNPs. For the
analyses of European subjects, we included the first six principal components as covariates,
together with a seventh component derived specifically for one study (LMBC) for which
there was substantial inflation not accounted for by the components derived from the
analysis of all studies (this component was set to zero for all other studies). The addition of
further principal components did not reduce inflation further. We included two principal
components each for the studies in Asian and African-American populations.
We excluded SNPs with call rates of <95%. We also excluded SNPs that deviated from
Hardy-Weinberg equilibrium in controls at P < 1 × 10−7, on the basis of a stratified 1-
degrre-of-freedom test in which the deviations were summed across strata67. We also
excluded SNPs for which the genotypes were discrepant in more than 2% of duplicate
samples across all COGS consortia. The final analyses were based on data from 199,961
SNPs.
Genotype intensity cluster plots were examined manually for SNPs in each new region in
which a genome-wide significant association was obtained, and SNPs were eliminated if the
clustering was judged to be poor.
Statistical analysis
For each SNP, we estimated a per-allele log(OR) and standard error by logistic regression,
including study and principal components as covariates. Genotype-specific ORs were also
computed. Overall significance levels were obtained by combining the estimates from the
combined GWAS and iCOGS using a fixed-effects meta-analysis to derive a 1-degree-of-
freedom test. Inflation of the test statistics (λ) was estimated by dividing the 45th percentile
of the test statistic by 0.357 (the 45th percentile for a χ2 distribution on 1 degree of
freedom). For this purpose, we used a subset of 22,897 SNPs that were uncorrelated (r2 <
0.1), which were not selected by BCAC and were not within 1 of the 4 common fine-
mapping regions. This subset was used to minimize the selection of SNPs associated with
disease, on the assumption that such SNPs are likely to be representative of common SNPs
in terms of population structure. The inflation statistic was converted to an equivalent
inflation statistic for a study with 1,000 cases and 1,000 controls (λ1,000) by adjusting by
effective study size, namely
where nk and mk are the number of cases and controls, respectively, for study k.
Heterogeneity in the per-allele OR by ER status, age at diagnosis, family history and tumor
invasiveness (DCIS versus invasive) were evaluated using a case-only analysis.
Expression analysis
Gene expression, copy number and genotype data were retrieved from the TCGA breast
cancer study. Gene expression profiles were measured by TCGA using a custom Agilent
244K expression array. We downloaded the raw expression data and performed
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preprocessing using the limma R package. Copy number and germline genotype were both
measured using the Affymetrix Genome-Wide Human SNP 6.0 array. We used the
segmented copy number and called genotype data as provided by TCGA. Intersecting the
different genomic data types, we collected 458 primary tumor samples with germline
genotypes from blood and both gene expression and somatic copy number data from the
tumor. In addition, for 61 samples, we had germline genotype and gene expression data from
normal breast tissue from individuals in the TCGA breast cancer study. Expression
quantitative trait locus (eQTL) analysis was performed on both sets separately. For cis-
eQTL analysis, we considered all genes 50 kb upstream or downstream of the lead SNP.
Fourteen of the risk-associated SNPs are represented directly on the Affymetrix SNP array.
For an additional 23, we were able to select proxies on the basis of maximum LD with
minimum r2 of 0.5. In case of equal LD, we used proximity on the genome to break the tie.
LD estimates were extracted from the HapMap data for the CEU population. eQTL analysis
was performed by regressing the gene expression of selected candidate genes on the
genotype followed by a significance test of the t statistic for the genotype covariate. For both
the normal and tumor analyses, the linear regression was adjusted for potential batch effects
by including indicator variables for the plate identifier component of the TCGA sample
barcode. In addition, the first principal component of the complete gene expression matrix
was added as a covariate to adjust for other global, typically non-genetic contributions to the
gene expression signal. To prevent spurious associations due to confounding by nearby
eQTLs, we corrected the model for the most strongly associated eQTL SNP in the region.
For the tumor analysis only, we also added the copy number of the candidate gene as a
covariate because apparent associations between germline genotype and tumor expression
may be confounded or obscured by somatic copy number alterations.
To assess the potential effects of the new SNPs on nearby gene expression in lymphocytes,
we identified all genes that lie within a 500-kb window surrounding each of the SNPs and
used Genevar (Gene Expression Variation), a public database with gene expression data
quantified in lymphocytes from individuals in the HapMap 2 populations35,68.
Estimation of the number of associated loci
To estimate the total number of newly associated loci selected for the iCOGS array, we first
used the set of 29,807 SNPs selected from the GWAS and not selected for fine mapping, to
exclude previously known loci. We then defined a set of 10,668 SNPs that were
uncorrelated (r2 < 0.1 between any pair) and determined the number of loci for which the
estimated effect size in the iCOGS stage was in the same direction as in the combined
GWAS and the number of loci for which the effect was in the opposite direction. Similar
results were obtained using cutoffs of r2 < 0.05 and r2 < 0.2. On the assumption that none of
the loci with effects in opposite directions in the two stages were associated with disease, the
number of loci associated with disease can be estimated as the difference between the
number of loci with effects in the same direction and the number with effects in opposite
directions. This, however, is an underestimate because loci with weak effects may have
estimated effects in opposite directions in the two stages. To allow for this possibility, we
fitted the distribution of z scores as a mixture of a standard normal distribution (representing
SNPs with no effect) and a normal distribution with unknown mean and variance, using an
expectation-maximization algorithm58. The total contribution to heritability was then
computed from the posterior estimates. To allow for the potential effect of residual
population stratification, we conducted an additional analysis in which the null distribution
was assumed to have variance of 1.2, based on the estimated inflation from the non-BCAC
SNPs, but the estimates were essentially identical.
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Figure 1.
One-degree-of-freedom trend-test statistics for 29,807 iCOGS SNPs selected from the
combined GWAS, excluding those occurring in known susceptibility regions. The red
horizontal line represents P = 5 × 10−8. The blue horizontal line represents P = 1 × 10−5.
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Figure 2.
Distribution of normalized effect sizes (z scores) in the iCOGS stage, with the direction of
effect determined by the direction in the combined GWAS. The blue curve represents the
standard normal distribution. The green curve represents the best-fit normal distribution
(mean = 0.19, s.d. = 1.22).
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